XYLANASE-MUTANTE

European patent · EP3670654 · In force

Register entry

Publication number
EP3670654
Application number
EP18845993
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 19, 2018
Published
Jun 24, 2020
Granted
Oct 1, 2025
Protection ends at the latest
Apr 18, 2038
Next annual fee due
Apr 30, 2026
IPC classes
C12N 9/42 (2006.01)
C12N 15/56 (2006.01)
C12N 15/81 (2006.01)
C12N 1/19 (2006.01)
C12R 1/84 (2006.01)
Priority
CN 201710712383 18.08.2017
PCT application
PCT/CN2018/083635 19.04.2018
PCT publication
WO2019/033775 21.02.2019
Filing language
Chinese
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 12, 2026

    Change

    Published in Swissreg on 12.08.2026

  2. Oct 1, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 01.10.2025

Parties

Holder

Qingdao Vland Biotech Group Co. Ltd.

Room 12A07 Shandong Expressway Mansion No. 29 Miaoling Road Laoshan District, Qingdao, Shandong 266061, CN

Inventor

WU, Xiuxiu

Shandong 266101, CN

SHAO, Chao

Shandong 266101, CN

HUANG, Yijun

Shandong 266101, CN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.